Breaking News Instant updates and real-time market news.

STJ

St. Jude Medical

$81.28

0.42 (0.52%)

, ABT

Abbott

$43.50

0.53 (1.23%)

07:39
10/11/16
10/11
07:39
10/11/16
07:39

St. Jude warns patients about premature battery depletion of defibrillators

St. Jude Medical (STJ), which is in the process of being purchased by Abbott Labs (ABT) and has recently been the target of short-seller Carson Block's firm Muddy Waters, is now warning patients that the batteries on some of its implantable defibrillators can unexpectedly deplete. In an "Important Medical Device Advisory" posted to the company's website, St. Jude stated: "On October 11, we issued a field advisory related to premature battery depletion associated with lithium deposits in a subset of our ICD and CRT-D devices manufactured before May 23, 2015. While it is a rare occurrence - 0.21%- we want to ensure we are providing the information physicians need to best care for their patients. We have consulted extensively with our Medical Advisory Board, other leading experts and regulatory agencies worldwide, and have the following recommendations for physicians and patients: We have asked physicians to contact their patients with information about this advisory. Device replacement is not recommended unless the physician determines otherwise. Our devices are designed to provide a vibratory alert when the battery is nearing depletion. Patients should always contact their physician immediately when they experience the vibratory alert. Premature battery depletion can be detected during doctor office visits and through remote monitoring. We recommend that patients enroll in Merlin.net remote monitoring service in countries where it is available. This service notifies a physician when the device's battery is nearing depletion. Patients with affected devices can discuss enrollment with their physician, and St. Jude Medical will provide the service at no cost. If the decision is made to replace an affected device based on a patient's circumstances, St. Jude Medical will provide a replacement device at no cost. None of St. Jude Medical's pacemakers are affected by this advisory as they are powered by low voltage batteries. Our highest priority is the safety of patients depending on our life sustaining technology and we are working with regulators and physicians to communicate about this advisory and the resources we are providing to assist with patient management." Patients can learn if their device is included in the advisory by visiting a dedicated webpage: Reference Link

STJ

St. Jude Medical

$81.28

0.42 (0.52%)

ABT

Abbott

$43.50

0.53 (1.23%)

  • 19

    Oct

  • 19

    Oct

  • 26

    Oct

  • 06

    Nov

STJ St. Jude Medical
$81.28

0.42 (0.52%)

08/29/16
RHCO
08/29/16
NO CHANGE
RHCO
St. Jude Medical deal unlikely to be impacted by negative report, says SunTrust
After Muddy Waters discussed weaknesses in St. Jude's (STJ) cybersecurity ecosystem, SunTrust analyst Bruce Nudell does not expect the company's CRM products to be recalled and does not believe that its Merlin remote monitoring system will be disabled. Consequently, the analyst does not expect the company's pending acquisition by Abbott (ABT) to be terminated or re-priced. The analyst keeps a Neutral rating on St. Jude.
08/29/16
FBCO
08/29/16
NO CHANGE
FBCO
St. Jude Medical can fix security deficiencies, says Credit Suisse
After speaking with "a developer of software used in drugs/devices" about Muddy Waters' security concerns regarding St. Jude's CRM system, Credit Suisse analyst Matthew Keeler says the consultant believes that the security deficiencies,can be fixed. According to the consultant, the deficiencies can be fixed using a five to ten person team working for about three months, Keeler stated. Keeler does not think that St. Jude's pending acquisition by Abbott (ABT) will be impacted by Muddy Waters' report. He keeps an $81 price target and Neutral rating on St. Jude.
09/08/16
PIPR
09/08/16
NO CHANGE
Target $82
PIPR
Neutral
Piper sees little reason to believe St. Jude deal will not close
Piper Jaffray analyst Brooks West says cybersecurity expert Mark Lanterman during a conference call yesterday refuted security claims by MedSec and Muddy Waters against St. Jude Medical's (STJ) pacemakers, defibrillators and Merlin monitoring system. Lanterman stated that there is "not much meat on the bone" to the MedSec claims and the quality of the analysis, West tells investors in a research note. He notes that Abbott (ABT) yesterday at a competitor conference earlier stated the St. Jude acquisition was progressing toward a close before year-end. The analyst sees little reason to believe the transaction will not close in the planned timeframe. West reiterates a Neutral rating on St. Jude.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
ABT Abbott
$43.50

0.53 (1.23%)

09/19/16
LEER
09/19/16
NO CHANGE
LEER
Abbott, Johnson & Johnson transaction positive for both companies, says Leerink
Leerink analyst Danielle Antalffy says the sale of Abbott's (ABT) Medical Optics ophthalmology business to Johnson & Johnson (JNJ) is positive for both companies. The deal strengthens Abbott's balance sheet and eliminates the need for a previously expected $3B capital raise, and adds a key component to Johnson & Johnson's already-strong vision care franchise, the analyst notes.
09/29/16
COWN
09/29/16
NO CHANGE
COWN
Outperform
Cowen says views on Dexcom, Insulet not changed by competitor launches
Cowen analyst Doug Schenkel noted that Abbott (ABT) announced yesterday it had received FDA approval for the professional version of its FreeStyle Libre glucose monitoring product and filed the consumer version of Libre, while Medtronic (MDT) also announced FDA approval of its 670G Hybrid Closed Loop system. Schenkel said Abbott's consumer Libre filing comes a few months ahead of his expectations but that Medtronic's timing was in-line with expectations. The analyst said the competitor announcements, which had been expected, do not change his views on DexCom (DXCM), Insulet (PODD), or Tandem Diabetes (TNDM) and he keeps Outperform ratings on all three of those stocks.
09/29/16
ADAM
09/29/16
NO CHANGE
Target $53
ADAM
Buy
Alere risk-reward looks 'quite good' as deal debate nears end, says Canaccord
Canaccord analyst Mark Massaro said he is optimistic that a conclusion of Abbott (ABT) and Alere's (ALR) merger fight is "not far off" and he still believes Abbott will ultimately acquire Alere, though he also thinks the merger may be decided by a judge. Massaro puts a 65% probability on the likelihood the deal closes at the $56 deal price, a 30% chance that Abbott buys Alere at a lower price nearer to $50 per share, and only a 5% chance the deal breaks, making the risk-reward ratio in Alere shares at current levels "quite good," he tells investors. He trimmed his price target on Alere to $53 from $56 an keeps a Buy rating on the stock.
09/29/16
BARD
09/29/16
NO CHANGE
BARD
Dexcom, Insulet could be weighed down by competitive concerns, says Baird
Baird analyst Jeff Johnson said that while the FDA approvals announced yesterday for Abbott's (ABT) FreeStyle Libre Pro and Medtronic's (MDT) 670G were largely anticipated, he believes that both approvals came sooner than most expected, as did news that Abbott also recently filed for FDA approval of its consumer Libre system. The approvals could "change the narrative" in diabetes and could weigh on others in the sector in the near-term, most notably Dexcom (DXCM) and Insulet (PODD), Johnson tells investors. He keeps Neutral ratings on both and maintains an Overweight rating on Tandem Diabetes (TNDM), citing valuation for the difference.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.